JonesTrading analyst Soumit Roy has maintained their bullish stance on OKUR stock, giving a Buy rating on March 13.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Soumit Roy has given his Buy rating due to a combination of factors that relate to both upcoming catalysts and the underlying clinical profile of OnKure’s lead asset, OKI-219. He views the imminent multi-cohort PIKture-1 breast cancer update not as a binary risk, but as an important interim step toward a more mature data readout over the next 9–12 months, with at least six months of follow-up expected to clarify efficacy and safety in mono and combo settings.
Roy also highlights that the update should show durability metrics, potentially including median progression-free survival, allowing comparison versus both fulvestrant and emerging PI3Kα competitors such as Relay’s zovegalisib, while appropriately adjusting for differences in line of therapy. Although triplet data with fulvestrant and ribociclib will be early, he believes it will meaningfully inform the safety profile and initial efficacy of the frontline strategy, supporting upside optionality ahead of more mature cohort updates, which underpins his positive stance and $17 price target.
In another report released on March 13, LifeSci Capital also maintained a Buy rating on the stock with a $21.00 price target.